Ocular Surface Disease and Quality of Life in Patients With Glaucoma

Grants

Funding Acknowledgements

THE AUTHORS INDICATE NO FUNDING SUPPORT. I.G. INDICATES ADVISOR AND TRAVEL SUPPORT FROM ALCON, ALLERGAN, MSD, and Pfizer; research support from Alcon, Allergan, and Pfizer; and participation as presenter in sessions sponsored at meetings for Alcon and Pfizer. P.M. indicates travel support from Alcon and research support from Novartis. Involved in design and conduct of the study (S.S., I.G., P.M.); collection, management, analysis, and interpretation of the data (SS., I.G., P.M.); and preparation, review, or approval of the manuscript (S.S., I.G., P.M.). The study protocol (17.09) was prospectively approved by the Human Research Ethics Committee of the Royal Australian and New Zealand College of Ophthalmologists, Sydney, Australia. The authors confirm that they are in compliance with their Institutional Review Board requirements. Informed consent was obtained from each participant. Approval was granted by Allergan for the use of the OSDI scoring system.